Breaking News

Synta Names CEO

August 6, 2014

Whitaker brings more than 20 years of pharma experience

Anne Whitaker has been appointed president and chief executive officer of Synta Pharmaceuticals Corp., and will serve on the board of directors, effective September 2. Ms. Whitaker has more than 20 years of experience in the pharmaceutical industry, having held executive roles at GlaxoSmithKline and Sanofi.
Most recently, Ms. Whitaker served as president, North America Pharmaceuticals at Sanofi, where she oversaw all pharmaceutical and consumer healthcare operations within the region, including the Diabetes, Oncology, Cardiovascular and other Patient Centered Units, Chattem (CHC), U.S. Market Access, U.S. Medical and Regulatory Affairs, Business Strategy, Planning & Operations and Canada Pharmaceuticals. She also served as a member of Sanofi’s Global Leadership Team, Global Commercial Operations Committee and U.S. Regional Management Committee.
At GSK, she held various positions in the commercial organization, serving as vice president of Critical and Supportive Care, senior vice president of Leadership and Organization Development, and senior vice president and business unit head, Cardiovascular, Metabolic and Urology (CVMU).
“It is with great pleasure that the Board welcomes Anne Whitaker as Synta’s new chief executive officer,” said Keith Gollust, chairman of the board of Synta. “Anne brings a wealth of experience to Synta, gained over a distinguished career in executive roles with two of the world’s top pharmaceutical companies. Her knowledge and experience in business strategy, product development, regulatory affairs, leadership and organizational development and commercialization will be invaluable to the Company as we continue to advance ganetespib through late stage development.”

Related Compliance:

blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus